Physician profile
Michael I Keller
NPI 1669541827
$4,535.40
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,501 · 2020: $1,034.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $497.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $489.18 | 2019-2020 | |
| Amgen INC. | $463.79 | 2019-2020 | |
| Abbvie INC. | $374.19 | 2019-2020 | |
| Horizon Therapeutics Plc | $369.44 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $360.55 | 2019 | |
| Glaxosmithkline, LLC. | $314.90 | 2019-2020 | |
| Gilead Sciences, INC. | $231.87 | 2019 | |
| Lilly USA, LLC | $225.81 | 2019-2020 | |
| Medexus Pharma, INC. | $171.20 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $167.46 | 2020 | |
| Celgene Corporation | $162.17 | 2019 | |
| Radius Health, INC. | $149.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $109.93 | 2019 | |
| Ucb, INC. | $105.13 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $56.02 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $54.45 | 2019-2020 | |
| Genentech USA, INC. | $52.20 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.12 | 2019 | |
| Genzyme Corporation | $26.19 | 2019 | |
| Orthogenrx INC. | $26.15 | 2019 | |
| Antares Pharma, INC. | $21.17 | 2019 | |
| Boston Scientific Corporation | $18.28 | 2020 | |
| Merck Sharp & Dohme LLC | $14.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.61 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.